Skip to main content
Caplight Logo









PellePharm

PellePharm

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://pellepharm.com

Last Round

Series C

Nov 20, 2018

Total Funding Raised

$94.5M

Company Overview

PellePharm is a biotechnology company that develops precision medicine therapies for rare dermatological conditions, including Gorlin Syndrome and Basal Cell Carcinomas.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalGorlin Syndromebasal cell carcinomaBCCtopical drughedgehog pathway inhibitordermatologyrare diseaseorphan drugclinical stagedrug developmentnevoid basal cell carcinoma syndromeNBCCSbiotechpharma partnering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PellePharm Comparables

Compare PellePharm with similar companies based on industry and business-model similarity.

PellePharm comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DermBiont
86%
Sol-Gel Technologies Ltd.
83%
Inhibitor Therapeutics, Inc.
81%

PellePharm Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 20, 2018
Series BJul 31, 2017
Series AJul 1, 2015

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 31, 2017

    $20M round led by BridgeBio Pharma

PellePharm Filings

Explore SEC and related filing metadata, where available.

PellePharm filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PellePharm's valuation, stock price, and market status.

Is PellePharm a public or private company?

PellePharm is a private company.

What is the current stock price of PellePharm?

PellePharm is a private company with no public stock price. No recent secondary market data is available.

How much is PellePharm worth (valuation)?

Valuation information for PellePharm is not publicly available.

Can I buy PellePharm stock?

PellePharm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PellePharm's last funding round?

PellePharm's most recent funding round was Series C on November 20, 2018.

Who are the main investors in PellePharm?

Investor information for PellePharm is not publicly disclosed.

Will PellePharm IPO soon?

No public IPO plans have been announced for PellePharm.

How can I track PellePharm secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PellePharm's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Year Founded2012
Last FundingNov 20, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?